PSY61 Comparative Pharmacoeconomic Analysis of the Application of Posaconazole, Fluconazole and Itraconazole With the Purpose of Primary Prevention of Invasive Fungal Infection In Patients With Neutropenia During Chemotherapy for Acute Myelogenous Leukemia Or Myelodysplastic Syndrome  by Krysanov, I. & Krysanova, V.
A532  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
ment in chronic HCV infected patients with thrombocytopenia to enable INF-based 
treatment regimens from the Spanish Health System perspective. Methods: A 
two-phase individual-level model was developed to evaluate the cost-effectiveness 
of eltrombopag treatment in thrombocytopenic HCV-patients over a lifetime hori-
zon. Individual-level models are more flexible and provide more accurate estima-
tions than Markov approaches. One million patients were simulated using data from 
trials ENABLE 1 and 2 and local studies. In the first phase, a discrete event simulation 
was used to recreate patient events during INF-treatment. When eltrombopag was 
considered, patients underwent an initial pre-INF treatment with eltrombopag. 
Those that failed to reach INF-label platelet count did not receive INF-based regi-
mens. In the second phase, a microsimulation was used to emulate each patient 
from treatment discontinuation to death. Health states included fibrosis (F0, F1/2, 
F3, F4), liver decompensation, hepatocelullar carcinoma, liver transplant and death. 
Transition probabilities for each 1-month cycle, utilities and direct health care costs 
(€ 2014) were obtained from literature and national databases. A 3% annual discount 
was applied to costs and health outcomes. Sensitivity analysis with 0% and 5% 
discount rates were performed. Results: Eltrombopag was associated with an 
average increment of 0.58 quality-adjusted life years (QALY) and an additional cost 
of € 17,084.47/patient. The average incremental cost effectiveness ratio (ICER) was 
29,808.26 € /QALY. Considering a € 30,000 threshold, eltrombopag was cost-effective 
in 59.12% of cases. This proportion remained similar with 5% (56.7%) and 0% (63.25%) 
discount rates. ConClusions: With the premises considered in this study, eltrom-
bopag in HCV patients could be considered cost-effective from the Spanish Health 
System perspective.
PSY63
CoSt-EffECtivEnESS of RomiPloStim foR thE tREatmEnt of ChRoniC 
immunE thRomboCYtoPEnia in PoRtugal
Augusto M.1, Gouveia M.2, Borges M.3, Campioni M.4
1Evigrade, Health Care Research and Consulting, Lda, Lisboa, Portugal, 2Católica Lisbon School 
of Business and Economics, Lisbon, Portugal, 3University of Lisbon, Lisbon, Portugal, 4Amgen 
(Europe) GmbH, Zug, Switzerland
objeCtives: To assess the cost-effectiveness of romiplostim in the treatment of 
Adult Immune Thrombocytopenia (ITP) in Portugal, versus eltrombopag and current 
medical standard of care (SoC). Methods: A lifetime treatment-sequence cost-utility 
Markov model with an embedded decision tree was developed from the Portuguese 
Healthcare Payer perspective to compare romiplostim with eltrombopag and SoC in 
splenectomized patients, non-splenectomized patients and a combined population. 
Treatment sequences and health care utilization were validated by a Portuguese 
expert in ITP. Outcomes included incremental cost-utility ratio (ICUR). Costs (€ , 2014) 
included drug acquisition costs and costs associated with monitoring patients and 
managing complications. Results: In the combined population, romiplostim versus 
eltrombopag had incremental costs (IC) of 13.848€ and a quality-adjusted life-years 
(QALY) gain of 0,566, yielding an ICUR of 24.451€ . Compared with SoC, romiplostim 
had IC of 18.622€ and a QALY gain of 0,938, yielding an ICUR of 19.848€ . In splenecto-
mized patients, the most prevalent sub-population in Portugal (65% of adult chronic 
ITP patients), romiplostim had an ICUR of 6.304€ versus eltrombopag and an ICUR 
of 3.179€ versus SoC. One-way sensitivity analysis showed that the model was most 
sensitive to variations in the drug doses/ percentage of utilization and costs (romi-
plostim, eltrombopag and intravenous immunoglobulin) and to the utility of patients 
responding to ITP treatments. In the combined population the probabilistic sensitiv-
ity analysis showed that romiplostim is likely to be cost-effective in 66% and 84% of 
samples versus eltrombopag and versus SoC at a willingness-to-pay threshold of 
30.000€ /QALY, respectively. ConClusions: Use of romiplostim in the ITP treatment 
pathway, compared with eltrombopag or SoC, is likely to be cost-effective in Portugal.
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objeCtives: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune inflam-
matory disease, associated with significant health and socioeconomic burden. 
Current treatment of SLE involves glucocorticoids, antimalarials, non-steroid anti-
inflammatory drugs, and immunosuppressive agents. Belimumab, a human IgG 
monoclonal antibody specific for soluble human B lymphocyte stimulator protein, 
is a novel pharmaceutical treatment approved as an add-on therapy in adult SLE 
patients with highly active disease (autoantibody-positive and low complement 
levels) despite treatment. The study objective was to estimate the incremental 
cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR) of adding 
belimumab to the Standard-of-Care (SoC) treatment of SLE patients with high dis-
ease activity in the Greek health care setting. Methods: The analysis is based on 
the local adaptation of a micro-simulation model. The model follows individual 
patients over a lifelong period. Data on short-term outcomes were sourced from two 
randomized controlled trials (BLISS 72/7614). Long-term outcomes were estimated 
via natural history models developed on the basis of data from the John Hopkins 
cohort of SLE patients. Direct costs consisted of short-term disease activity related 
costs, organ damage costs, SoC treatment and belimumab administration costs. 
Short-term costs and costs of treatment were calculated on the basis of resource 
utilisation elicited from a panel of experts and using list prices (2013 prices). Organ 
damage costs were identified through a literature review. Results were discounted at 
3.5% for both costs and effects. The study was performed from the perspective of the 
health care payer. Results: Treatment with belimumab+SoC resulted in 0.81 added 
life years and 0.377 QALYs (Quality-Adjusted Life Years). This resulted in 18,350€ / 
LYG (Life-Year-Gained) and 27,254€ /QALY. ConClusions: Cost-effectiveness and 
cost-utility ratios of belimumab compared to SoC treatment are below internation-
ally applied thresholds. Belimumab can be considered as an add-on therapy to SoC 
for the treatment of SLE patients with highly active disease in Greece.
strength of the analysis, deterministic and probabilistic sensitivity tests were per-
formed; all the quantities are expresed in Mexican pesos (MXP) at 2013. Results: 
Both groups lose weight and reduce their BMI. However, these changes were earlier 
and more pronounced in the (DEP+DaE) group. DeP+DaE presented a significant 
higher percentage of patients reducing 10% of their intial weight (37% vs 17%, 
p-value< .05). Incremental cost was $1,455.09 MXP and incremental effectiveness 
was 20% in reducing the initial weight. The incremental cost-effectiveness ratio of 
(DEP+DaE) relative to DaE was calculated to be $7,374.07 MXP per additional percent-
age of reduction suggesting that DEP+DaE is cost-effective compared with DaE as 
a treatment for obesity in Mexico. ConClusions: The combination of DEP+DaE 
provides a cost effective improvement to the treatment of patients with a risk profile 
for obesity in Mexico.
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objeCtives: To perform a complete economic evaluation type using oxycodone 
(Endocodil XR ®) versus morphine, buprenorphine (transdermal patches) and fen-
tanyl (transdermal patches) on moderate to severe pain secondary to cancer type 
in Mexico, from the point of view of public health. Methods: A cost-effectiveness 
analysis was made, a decision tree model was developed to simulate the costs and 
benefits of health outcomes of each opioid analgesic, the probabilities were obtained 
through a systematic review of the literature. The model has 13 cycles of 28 days 
under a time horizon of 364 days, the main measure of effectiveness was deter-
mined as days without severe adverse events and pain controlled, only measured 
direct medical costs and the ratio was obtained incremental cost-effectiveness, 
further a deterministic sensitivity analysis, probabilistic sensitivity analysis and 
budget impact was performed. Results: The results demonstrate that oxycodone 
(Endocodil XR ®) is a dominant option respect to Buprenorphine (PT), fentanyl (PT), 
the results showed 309 days without severe adverse events and controlled pain 
compared to 219 and 255 respectively Oxycodone had a cost of $ 57,702.34 under $ 
58,254.43 and 129,906.49 costing of their comparators respectively, compared to mor-
phine oxycodone is more effective but more expensive, it had an ICER of $ 202.05, 
sensitivity analysis and budget impact showed that oxycodone remains an option 
cost-saving. ConClusions: The results demonstrate that oxycodone (Endocodil XR 
®) is a cost-effective option for the treatment of patients with pain of moderate to 
severe secondary to cancer in Mexico, it is an option that effectively combines price 
and fails to meet the necessary standards for palliative care and pain management.
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objeCtives: To perform ñomparative pharmacoeconomic analysis of alternative 
schemes for prevention of invasive mycosis with fluconazole, itraconazole and 
posaconazole in patients with neutropenia, after chemotherapy for acute myelog-
enous leukemia or myelodysplastic syndrome. Methods: Were reviewed research 
on the clinical effectiveness and safety of use of Posaconazole. Assess of the qual-
ity of research and level of evidence obtained in these results was performed. The 
model is constructed on the basis of the results of a multicenter randomized trial 
Cornely O. A. et al., 2007. The model calculated the differences in direct medical 
costs for the use of drugs, as well as the cost of medical treatment cases inva-
sive mycosis the ineffectiveness of primary prevention. The duration of preventive 
treatment, the probability of various outcomes correspond to the data of speci-
fied clinical study. Results: Analysis of the evidence has shown that on patients 
with neutropenia antifungal prophylaxis with posaconazole is more effective than 
fluconazole/itraconazole, and significantly reduces the risk of developing invasive 
mycosis, and associated mortality. Total costs for the use of posaconazole was 13169 
USD, that by 24.6 % higher than the use of fluconazole (total costs 9932 USD) and 
24.3 % higher than itraconazole (total costs 9965 USD). Also use of posaconazole has 
increased the total number of LYG by 6%. The ICER was $ 21339 USD and 21117 USD 
compared to fluconazole and itraconazole, and lower than the estimated threshold 
of willingness to pay in the Russian Federation equal 38390 USD. One-way sensi-
tivity analysis showed that in case of changes in the cost of posaconazole from 
75% to 125 %, the ICER for a one LYG do not exceed the threshold of willingness 
to pay. ConClusions: Use of Posaconazole for prevention of invasive mycosis in 
patients with neutropenia is economically justified.
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objeCtives: Thrombocytopenia limits the use of interferon (INF) based regimens 
in chronic hepatitis C virus (HCV) patients. Eltrombopag, a thrombopoietin-receptor 
agonist, effectively elevates platelet count allowing optimal INF-treatment. The 
objective of the present study was to assess the cost-effectiveness as support treat-
